CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Recent advances in machine learning and experimental biology have offered breakthrough
solutions to problems such as protein structure prediction that were long thought to be …

A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …

The accurate selection of neoantigens that bind to class I human leukocyte antigen (HLA)
and are recognized by autologous T cells is a crucial step in many cancer immunotherapy …

Identifying neoepitopes that elicit an adaptive immune response is a major bottleneck to
developing personalized cancer vaccines. Experimental validation of candidate …

Immune evasion is a hallmark of cancer, enabling tumors to survive contact with the host
immune system and evade the cycle of immune recognition and destruction. Here, we …

Different strategies based on peptides are available for cancer treatment, in particular to
counter-act the progression of tumor growth and disease relapse. In the last decade, in the …

Neoantigen vaccines are based on epitopes of antigenic parts of mutant proteins expressed
in cancer cells. These highly immunogenic antigens may trigger the immune system to …

Studies have characterized the immune escape landscape across primary tumors. However,
whether late-stage metastatic tumors present differences in genetic immune escape (GIE) …

Adoptive cell therapy using T cell receptor-engineered T cells (TCR-T) is a promising
approach for cancer therapy with an expectation of no significant side effects. In the human …